Latest & greatest articles for calcium

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on calcium or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on calcium and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for calcium

161. The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers

The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers 21242274 2011 02 23 2011 04 20 2017 02 20 1488-2329 183 3 2011 Feb 22 CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne CMAJ The risk of hypotension following co-prescription of macrolide antibiotics and calcium-channel blockers. 303-7 10.1503/cmaj.100702 The macrolide antibiotics clarithromycin and erythromycin may potentiate calcium-channel blockers (...) by inhibiting cytochrome P450 isoenzyme 3A4. However, this potential drug interaction is widely underappreciated and its clinical consequences have not been well characterized. We explored the risk of hypotension or shock requiring hospital admission following the simultaneous use of calcium-channel blockers and macrolide antibiotics. We conducted a population-based, nested, case-crossover study involving people aged 66 years and older who had been prescribed a calcium-channel blocker between Apr. 1, 1994

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

162. Calcium supplementation in adults is associated with a modest increased risk of myocardial infarction

Calcium supplementation in adults is associated with a modest increased risk of myocardial infarction Calcium supplementation in adults is associated with a modest increased risk of myocardial infarction ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Make a difference with dentistry's premier charitable organization Take (...) website Evidence Education About * Associated Topics Calcium supplementation in adults is associated with a modest increased risk of myocardial infarction Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Calcium supplementation, without coadministration of vitamin D, is associated with a modest increased incidence of myocardial infarction, which warrants a reassessment of its use in the management of osteoporosis. Critical Summary Assessment A high-quality

ADA Center for Evidence-Based Dentistry2011

163. Calcium supplementation in adults is associated with a modest increased risk of myocardial infarction

Calcium supplementation in adults is associated with a modest increased risk of myocardial infarction Calcium supplementation in adults is associated with a modest increased risk of myocardial infarction ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Take advantage of endorsed, discounted business products Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Make a difference (...) Evidence Education About * Associated Topics Calcium supplementation in adults is associated with a modest increased risk of myocardial infarction Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Calcium supplementation, without coadministration of vitamin D, is associated with a modest increased incidence of myocardial infarction, which warrants a reassessment of its use in the management of osteoporosis. Critical Summary Assessment A high-quality of good

ADA Center for Evidence-Based Dentistry2011

164. Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7

Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7 21189381 2011 01 31 2011 03 10 2016 12 15 1527-7755 29 4 2011 Feb 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. 421-7 10.1200/JCO.2010.31.5911 Cumulative sensory neurotoxicity (sNT) is the dose (...) -limiting toxicity of oxaliplatin, which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant settings. In a nonrandomized, retrospective study, intravenous (IV) calcium/magnesium (Ca/Mg) was associated with reduced oxaliplatin-induced sNT. Patients with colon cancer undergoing adjuvant therapy with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) were randomly assigned to Ca/Mg (1g calcium gluconate plus 1g magnesium sulfate pre- and post

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

165. Systematic review: Vitamin D reduces the risk of falls in older adults compared with calcium or placebo

Systematic review: Vitamin D reduces the risk of falls in older adults compared with calcium or placebo Vitamin D reduces the risk of falls in older adults compared with calcium or placebo | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Vitamin D reduces the risk of falls in older adults compared with calcium or placebo Article Text Care of the older person Systematic review Vitamin D reduces the risk of falls in older adults compared with calcium or placebo Melissa J Benton Statistics from Altmetric.com

Evidence-Based Nursing (Requires free registration)2011

166. Prognosis of MTA Apexification Versus Calcium Hydroxide Apexification

Prognosis of MTA Apexification Versus Calcium Hydroxide Apexification UTCAT830, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Prognosis Of MTA Apexification Versus Calcium Hydroxide Apexification Clinical Question Does MTA apexification render better long-term prognosis than calcium hydroxide apexification for treatment of dens in dente in permanent dentition from children or adolescents? Clinical Bottom Line When (...) performed correctly, apexification with MTA and calcium hydroxide on permanent dentition with dens in dente and open apices both have similarly good long-term prognosis. However, given that MTA is more biocompatible and that it can be performed in one visit, MTA apexification is the treatment of choice. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Jaramillo/2006 Children to adolescent with dens in dente

UTHSCSA Dental School CAT Library2011

167. Calcium Channel Blockers and Enamel Demineralization

Calcium Channel Blockers and Enamel Demineralization UTCAT845, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Patients On Calcium Channel Blockers Should Be Monitored For Enamel Demineralization Clinical Question In patients taking calcium channel blockers [for the treatment of hypertension, angina, tachycardia, etc], has demineralization of the enamel been seen to a degree that a remineralization regimen would (...) be indicated? Clinical Bottom Line Yes, in the cited study, a significantly increased number of patients who underwent calcium antagonist therapy exhibited signs of “decalcination” and and dental caries, but this is not yet grounds for prophylactic remineralization. (See Comments on the CAT below) Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Ivanova/1999 100 taking calcium channel blocker vs. 60 not taking

UTHSCSA Dental School CAT Library2011

168. Formocresol vs Direct Pulp Capping with Calcium Hydroxide in Primary Teeth

Formocresol vs Direct Pulp Capping with Calcium Hydroxide in Primary Teeth UTCAT765, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Formocresol Vs Direct Pulp Capping with Calcium Hydroxide in Primary Teeth Clinical Question In children (4-5 years old) with carious primary molars, will the use of formocresol provide better long-term success with fewer side effects than traditional direct pulp capping with calcium (...) hydroxide? Clinical Bottom Line Formocresol is clinically successful and should be considered as an alternative to direct pulp capping with calcium hydroxide in carious primary molars. (See Comments on the CAT below) Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Aminabadi/2010 120 teeth (84 children) Randomized Controlled Trial Key results The prevalence of side effects such as pain, sensitivity

UTHSCSA Dental School CAT Library2011

169. Cost-effectiveness analysis regarding postoperative administration of vitamin-D and calcium after thyroidectomy to prevent hypocalcaemia

Cost-effectiveness analysis regarding postoperative administration of vitamin-D and calcium after thyroidectomy to prevent hypocalcaemia Cost-effectiveness analysis regarding postoperative administration of vitamin-D and calcium after thyroidectomy to prevent hypocalcaemia Cost-effectiveness analysis regarding postoperative administration of vitamin-D and calcium after thyroidectomy to prevent hypocalcaemia Sanabria A, Dominguez LC, Vega V, Osorio C, Duarte D Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined cost-effectiveness of routine postoperative administration of vitamin D or metabolites and calcium to reduce the incidence of hypocalcaemia after total thyroidectomy. The authors concluded that both

NHS Economic Evaluation Database.2011

170. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial.

Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. 21236483 2011 01 24 2011 03 17 2015 06 16 1474-547X 377 9762 2011 Jan 22 Lancet (London, England) Lancet Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. 312-20 10.1016/S0140-6736(10)62003-X Short-term (...) , University of Cambridge, Cambridge, UK. m.j.brown@cai.cam.ac.uk McInnes Gordon T GT Papst Cheraz Cherif CC Zhang Jack J MacDonald Thomas M TM eng ClinicalTrials.gov NCT00797862 Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't 2011 01 12 England Lancet 2985213R 0140-6736 0 Amides 0 Antihypertensive Agents 0 Calcium Channel Blockers 0 Fumarates 1J444QC288 Amlodipine 502FWN4Q32 aliskiren AIM IM Curr Hypertens Rep. 2011 Aug;13(4):259-61 21494776 Evid Based Med

Lancet2011

171. Calcium and vitamin D: no prescribing changes

Calcium and vitamin D: no prescribing changes Calcium and vitamin D: no prescribing changes Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Calcium and vitamin D: no prescribing changes From: Published: 13 October 2011 Therapeutic area: and Studies of cardiovascular risk don’t support prescribing changes. Article date: October 2011 A research article in 2010 by Bolland and colleagues seemed to show that calcium supplements without coadministered vitamin D (...) of calcium with or without vitamin D versus placebo. In the reanalysis of the WHI trial of calcium plus vitamin D versus placebo, the risk of clinical MI was slightly increased in women not self-medicating with calcium supplements at baseline who were randomly assigned to calcium plus vitamin D (HR 1.22 [1.00–1.50]; p=0.054), but this was of borderline significance. There were 209 events of clinical MI in the calcium plus vitamin D group compared with 168 events in the placebo group (an incidence of 3.5

MHRA Drug Safety Update2011

172. Phoslyra (calcium acetate)

Phoslyra (calcium acetate) Drug Approval Package: Phoslyra (calcium acetate) NDA #022581 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Phoslyra (calcium acetate) 667 mg/ 5mL oral solution Company: Fresenius Medical Care North America Application No.: 022581 Approval Date: 04/18/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2011

173. Effect of a high-calcium energy-reduced diet on abdominal obesity and cardiometabolic risk factors in obese Brazilian subjects

Effect of a high-calcium energy-reduced diet on abdominal obesity and cardiometabolic risk factors in obese Brazilian subjects 20642707 2010 07 20 2011 11 10 2010 07 20 1742-1241 64 8 2010 Jul International journal of clinical practice Int. J. Clin. Pract. Effect of a high-calcium energy-reduced diet on abdominal obesity and cardiometabolic risk factors in obese Brazilian subjects. 1076-83 10.1111/j.1742-1241.2009.02312.x Clinical trials designed to examine the effects of calcium (...) supplementation on abdominal obesity have had ambiguous results. This study aimed to evaluate, during energy restriction, the effects of a high-calcium diet (HCD) on measures of abdominal obesity and cardiometabolic risk factors in Brazilian obese subjects of multiethnic origin. We conducted a randomised clinical trial. Fifty obese subjects of both sexes, aged 22-55 years, with stable body weight and a low calcium intake were randomised into the following outpatient dietary regimens: (i) a low-calcium diet

EvidenceUpdates2010

174. Nonoptimal Lipids Commonly Present in Young Adults and Coronary Calcium Later in Life: The CARDIA (Coronary Artery Risk Development in Young Adults) Study.

Nonoptimal Lipids Commonly Present in Young Adults and Coronary Calcium Later in Life: The CARDIA (Coronary Artery Risk Development in Young Adults) Study. BACKGROUND: Dyslipidemia causes coronary heart disease in middle-aged and elderly adults, but the consequences of lipid exposure during young adulthood are unclear. OBJECTIVE: To assess whether nonoptimal lipid levels during young adulthood cause atherosclerotic changes that persist into middle age. DESIGN: Prospective cohort study. SETTING (...) : 4 cities in the United States. PARTICIPANTS: 3258 participants from the 5115 black and white men and women recruited at age 18 to 30 years in 1985 to 1986 for the CARDIA (Coronary Artery Risk Development in Young Adults) study. MEASUREMENTS: Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, triglycerides, and coronary calcium. Time-averaged cumulative exposures to lipids between age 20 and 35 years were estimated by using repeated serum lipid measurements over 20

Annals of Internal Medicine2010 Full Text: Link to full Text with Trip Pro

175. Coronary artery calcium score and risk classification for coronary heart disease prediction.

Coronary artery calcium score and risk classification for coronary heart disease prediction. CONTEXT: The coronary artery calcium score (CACS) has been shown to predict future coronary heart disease (CHD) events. However, the extent to which adding CACS to traditional CHD risk factors improves classification of risk is unclear. OBJECTIVE: To determine whether adding CACS to a prediction model based on traditional risk factors improves classification of risk. DESIGN, SETTING, AND PARTICIPANTS

JAMA2010 Full Text: Link to full Text with Trip Pro

176. Systematic review: vitamin d and calcium supplementation in prevention of cardiovascular events.

Systematic review: vitamin d and calcium supplementation in prevention of cardiovascular events. BACKGROUND: Vitamin D and calcium may affect the cardiovascular system independently and interactively. PURPOSE: To assess whether vitamin D and calcium supplements reduce the risk for cardiovascular events in adults. DATA SOURCES: Studies published in English from 1966 to July 2009 in MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials. STUDY SELECTION: Two investigators (...) independently selected 17 prospective studies and randomized trials that examined vitamin D supplementation, calcium supplementation, or both and subsequent cardiovascular events. DATA EXTRACTION: Three investigators extracted and checked data about study designs, participants, exposures or interventions, outcomes, and data quality. DATA SYNTHESIS: Five prospective studies of patients receiving dialysis and 1 study involving a general population showed consistent reductions in cardiovascular disease (CVD

Annals of Internal Medicine2010

178. A prospective randomized controlled trial of a bioresorbable calcium phosphate paste (alpha-BSM) in treatment of displaced intra-articular calcaneal fractures

A prospective randomized controlled trial of a bioresorbable calcium phosphate paste (alpha-BSM) in treatment of displaced intra-articular calcaneal fractures 19820600 2009 10 12 2009 12 02 2016 11 25 1529-8809 67 4 2009 Oct The Journal of trauma J Trauma A prospective randomized controlled trial of a bioresorbable calcium phosphate paste (alpha-BSM) in treatment of displaced intra-articular calcaneal fractures. 875-82 10.1097/TA.0b013e3181ae2d50 Displaced intra-articular calcaneal fractures (...) are devastating injuries and pose a therapeutic challenge. The purpose of this study was to determine whether open reduction internal fixation (ORIF) plus an injectable bioresorbable calcium phosphate paste (alpha-BSM [bone substitute material]) is superior to ORIF alone in the treatment of calcaneal bone voids encountered after operative treatment of displaced intra-articular calcaneal fractures. We prospectively randomized 47 patients with 52 closed displaced intra-articular fractures necessitating

EvidenceUpdates2010

179. Systematic review: Calcium supplements increase risk of myocardial infarction

Systematic review: Calcium supplements increase risk of myocardial infarction Calcium supplements increase risk of myocardial infarction | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Calcium supplements increase risk of myocardial infarction Article Text Therapeutics Systematic review Calcium supplements increase risk of myocardial infarction Sonal Singh 1 , Curt D Furberg 2 Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Bolland MJ , Avenell A , Baron JA , et al . Effect of calcium supplements on risk

Evidence-Based Medicine (Requires free registration)2010

180. Systematic review: Muscle cramps: quinine derivatives likely to be effective but not recommended for routine use due to toxicity; vitamin B complex, naftidrofuryl and calcium channel blockers possibly effective

Systematic review: Muscle cramps: quinine derivatives likely to be effective but not recommended for routine use due to toxicity; vitamin B complex, naftidrofuryl and calcium channel blockers possibly effective Muscle cramps: quinine derivatives likely to be effective but not recommended for routine use due to toxicity; vitamin B complex, naftidrofuryl and calcium channel blockers possibly effective | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you (...) to toxicity; vitamin B complex, naftidrofuryl and calcium channel blockers possibly effective Article Text Therapeutics Systematic review Muscle cramps: quinine derivatives likely to be effective but not recommended for routine use due to toxicity; vitamin B complex, naftidrofuryl and calcium channel blockers possibly effective Gavin Young Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Katzberg HD , Khan AH , So YT . Assessment: symptomatic treatment for muscle

Evidence-Based Medicine (Requires free registration)2010